• Positive results from Phase 1b azer-cel clinical trial CAR T-naive cohort
• Azer-cel Phase 1b protocol amended to add a BTKi combination arm and Mantle Cell Lymphoma (MCL) as an indication
• $16 million capital raising from institutional and retail shareholders

Imugene Limited, a clinical-stage immuno-oncology company, reported its Quarterly Activities and Cash Flow report for the quarter ended 31 March 2026. The company announced positive results from the Phase 1b azer-cel clinical trial CAR T-naive cohort, including a 100% overall response rate in CLL/SLL and an 80% overall response rate in MZL. Imugene also amended the Phase 1b protocol to evaluate azer-cel in combination with a Bruton Tyrosine Kinase inhibitor (BTKi) and added Mantle Cell Lymphoma (MCL) as an indication. During the quarter, Imugene received a $2.7 million R&D tax refund and raised $16 million through a capital raising from institutional and retail shareholders. The funds will support the ongoing development of azer-cel, including expansion of Cohort 2 and the new Cohort 3 BTKi combination arm of the Phase 1b trial, extending the funding runway into Q4 2026, and general working capital. The company also announced that azer-cel data was selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, reflecting the clinical merit of the program.

Imugene expects its net operating cash flows to be similar to lower for the time being, subject to annual short term incentive for CY2025 to be paid in April 2026. The company is continuing its focus on reducing working capital and expects to receive additional funds from a capital raising in the next quarter.

Key catalysts in the near term include the ASCO abstract publishing on 21 May 2026, ASCO oral presentations from 29 May to 2 June 2026, and updated data from the CAR T-naive expansion cohort and enrollment in the BTKi combination cohort.